12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Company News  |  Deals

Araclon, Grifols deal

Grifols acquired 51% of Alzheimer's disease (AD) company Araclon. The University of Zaragoza spinout launched its Abtest40 and Abtest42 blood-based AD...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >